TCTR20161214001已完成4 期
Efficacy and Safety of Subcutaneous Administration of Lyophilized Powder of Alpha-Erythropoietin to Maintains Hemoglobin Concentrations among Hemodialysis Patients
Phramongkutklao hospital and College of Medicine0 个研究点目标入组 63 人开始时间: 2016年12月14日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Eligibility included male and female patients aged 18 to 85 years diagnosed with CKD receiving hemodialysis who presented stable hemoglobin levels of 10-11.5 g/dL with standard liquid EPO alpha product (EPREX, CILAG AG, Switzerland) treatment at least 12 weeks. All patients had adequate dialysis by a single pool Kt/Vurea greater than 1.2 per dialysis treatment and adequate iron status (≥20% of transferrin saturation and ≥200 ng/mL of ferritin).
排除标准
- •Patients were excluded from the study if they were on peritoneal dialysis or had identified causes of anemia such as gastrointestinal hemorrhage, hematologic malignancy, chronic infection and nutritional anemia. In addition, patients were excluded if they were hyporesponsive to EPO (defined as an intravenous EPO dose of >360 IU/kg weekly or an intravenous darbepoetin dose of >1.8 mg/kg weekly) within the prior 12 weeks.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin beta. A multinational, multicentre, randomised, controlled, double-blind, comparative, parallel group Phase III study.anaemic chronic renal failure patients not yet receiving dialysisMedDRA version: 9Level: LLTClassification code 10009119EUCTR2005-000142-37-HUBioGeneriX AG255
招募中
2 期
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients.multiple myelomaJPRN-UMIN000007803ational Hospital Organization Disaster Medical Center35
进行中（未招募）
1 期
Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.EUCTR2007-006153-31-FRBaxter R and D Europe SCR120
招募中
3 期
Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitorsblood clothing disorderHaemophilia A10064477NL-OMON51874ovo Nordisk4